Atypical Teratoid Rhabdoid Tumor Treatment News and Information

What is an Atypical Teratoid Rhabdoid Tumor? (Definition)

Atypical teratoid rhabdoid tumor (ATRT) is a very rare (diagnosed in fewer than 10% of children with brain tumors) and aggressive tumor usually diagnosed in childhood. Although usually a brain tumor, ATRT can occur anywhere in the central nervous system (CNS) including the spinal cord. The tumor occurs mostly in the cerebellum (the part of the brain that controls movement and balance) or the brain stem (the part of the brain that controls basic body functions).
According to St. Jude children’s Research Hospital, ATRT often appears to result from changes in a gene that normally makes proteins to stop tumor growth. In ATRT, this gene does not function properly, the protein is not made and tumor growth is uncontrolled. More than 90% of cases of ATRT are related to this gene defect. While this defect commonly occurs only within the cancer, this gene defect may be inherited and your doctor can discuss a need for genetic testing.

Symptoms of ATRT may include the following:

  • Morning headaches or headaches that are less painful after vomiting
    Nausea and vomiting
    Changes in activity levels
    Feeling sleepy
    Loss of balance, increasing problems with coordination or trouble walking
    Asymmetric eye movements or face movements
    Increase in head size (in infants)

See below for updated news and information regarding Atypical Teratoid Rhabdoid Tumors including new medical research, treatment options and advancements. 

Latest Atypical Teratoid Rhabdoid Tumor Treatment News and Research


(SOURCE: UNIVERSITY HEALTH NETWORK) - Multi-institutional researchers investigating an incurable brain cancer in children have discovered three distinct subgroups of disease and identified  promising drugs to  target each type. The research findings are published online today and depicted on the cover of Cancer Cell. Co-principal investigator Dr. Daniel De Carvalho, Scientist at Princess Margaret Cancer Centre, says being able to ...
Read More